Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.56 |
| ▸ | CTRB1 | P17538 | 1/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | PRCP | P42785 | 1/20 | 0.49 |
| ▸ | GFER | P55789 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | PREP | P48147 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | CTSK | P43235 | 2/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | CTSL | P07711 | 1/20 | 0.46 |
| ▸ | KDM1A | O60341 | 1/20 | 0.46 |
| ▸ | RCOR1 | Q9UKL0 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8289059 | 1.00 | TSHR (0.56) | TSHRL3MBTL1CTRB1KDM4ELMNA | |
| SCHEMBL992994 | 0.84 | CTRB1 (0.64) | TSHRL3MBTL1CTRB1KDM4ELMNA | |
| SCHEMBL8287761 | 0.84 | CTRB1 (0.64) | TSHRL3MBTL1CTRB1KDM4ELMNA | |
| SCHEMBL5496992 | 0.84 | CTRB1 (0.52) | TSHRL3MBTL1CTRB1KDM4ELMNA | |
| SCHEMBL5496996 | 0.84 | CTRB1 (0.52) | TSHRL3MBTL1CTRB1KDM4ELMNA | |
| SCHEMBL8287700 | 0.83 | CTRB1 (0.58) | TSHRL3MBTL1CTRB1KDM4ELMNA | |
| SCHEMBL994089 | 0.83 | CTRB1 (0.58) | TSHRL3MBTL1CTRB1KDM4ELMNA | |
| SCHEMBL12950181 | 0.83 | CTRB1 (0.61) | TSHRL3MBTL1CTRB1KDM4ELMNA | |
| SCHEMBL993939 | 0.80 | CTRB1 (0.58) | TSHRL3MBTL1CTRB1KDM4ELMNA | |
| SCHEMBL7167010 | 0.80 | CTRB1 (0.53) | TSHRL3MBTL1CTRB1KDM4ELMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2270004-A1 | Caspase inhibitors and uses thereof | Vertex Pharmceuticals Incorporated (US) | 2011-01-05 | — | — | EP | disclosed |
| US-20100105914-A1 | CASPASE INHIBITORS AND USES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-04-29 | — | — | US | disclosed |
| US-7652153-B2 | Use in controlling apoptosis, as antiinflammatory agents, in treating autoimmune disease, as antiischemic agents, in treating cardiovascular disorders; for example, (S,S)-3-[2-(3-Acetylamino-2-oxo-2H-pyridin-1-yl)-butyrylamino]-4-oxo-5-(2,3,5,6-tetrafluoro-phenoxy)-pentanoic acid | VERTEX PHARMACEUTICALS INCORPORATED | 2010-01-26 | — | — | US | disclosed |
| US-20050233979-A1 | Caspase inhibitors and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED | 2005-10-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100105914-A1 | CASPASE INHIBITORS AND USES THEREOF | CASP1, CASP5, CASP3 | TSHR 4831/4885L3MBTL1 3706/4885CTRB1 205/4885 |
| US-20050233979-A1 | Caspase inhibitors and uses thereof | CASP1, CASP5, CASP3 | TSHR 4835/4885L3MBTL1 3584/4885CTRB1 188/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.